Alterations of the Gut Microbiome in Psoriasis before and after Treated with Secukinumab.

ABSTRACT:

Background

Psoriasis is a chronic inflammatory skin disease linked to immune system. Despite its prevalence, the precise aetiology and pathogenesis of psoriasis remain elusive. This study aimed to assess the efficacy and safety of Secukinumab while exploring its impact on the intestinal microbiota in patients with moderate-to-severe plaque psoriasis.

Materials and methods

We recruited 60 healthy controls and 110 patients with moderate-to-severe plaque psoriasis who attended outpatient clinics between June 2022 and June 2023. Clinical data (gender, age, BMI, PASI score, PGA, DLQI, Itch NRS, and STAI score) and faecal samples were collected from all groups. Faecal samples underwent PacBio Full-Length Diversity Sequencing and subsequent informatics analysis.

Results

Pati

SUBMITTER: Fang L 

PROVIDER: S-EPMC12830021 | biostudies-literature | 2026 Jan-Feb

REPOSITORIES: biostudies-literature